Liquidia Technologies receives US$3m to fund PRINT manufacturing process
US nanotechnology company Liquidia Technologies is to receive approximately US$3m (Euro 2.1m) in funding from the US Commerce Department's National Institute of Standards and Technology (NIST) to develop and scale up the company's PRINT manufacturing process.
US nanotechnology company Liquidia Technologies is to receive approximately US$3m (Euro 2.1m) in funding from the US Commerce Department's National Institute of Standards and Technology (NIST) to develop and scale up the company's PRINT manufacturing process.
The grant is made by NIST as part of its Technology Innovation Programme (TIP) to fund new cost-sharing projects to support innovative technologies that address critical national needs.
The company says the PRINT manufacturing process uses a proprietary roll-to-roll method that allows Liquidia to produce precisely engineered particles that offer safer and more efficient delivery of vaccine and therapeutic drug products. The capabilities realised as a direct result of this project will support the advancement of a platform of products, including the company's initial vaccine product, which is expected to enter clinical trials next year.
"We are very excited to have been selected by NIST as one of the 20 projects to receive funding through the TIP programme," said Tom Templeman, senior vice president, Integrated Supply Chain at Liquidia. "This investment will support our continued development of PRINT manufacturing, which will allow us to develop clinically relevant quantities of particles."
Liquidia Technologies is a privately held nanotechnology company that develops and manufactures precisely engineered particles for improved delivery of biological and small molecule therapeutics. The company is currently advancing products within the fields of vaccines, nucleic acid delivery, and inhaled therapeutics to address critical unmet needs.